Good morning folks, welcome to the start of another workweek. Grab a cup of coffee, juice or your favorite beverage on your way over to HCV Advocate to read all about genotypes in "HCV Advocates Mid-Month Newsletter."
HCV Advocate Mid-Month Newsletter
In This Issue:
HCV Genotypes
Alan Franciscus, Editor-in-Chief
This month’s column is about hepatitis C (HCV) genotypes. I will present a brief overview of genotypes 1, 2, 3, 4, and 6. You will notice that I am not discussing genotype 5, which is discussed more in-depth later in this issue, and Genotype 7, which is very rare.
Genotype 3: An Unmet Treatment Need for Some
Alan Franciscus, Editor-in-Chief
Alan Franciscus, Editor-in-Chief
While conducting a workshop in New England, I was asked a question about genotype 3 treatment for people who are treatment experienced and had cirrhosis—there are effective therapies, but I usually get a ‘yuck’ reaction when I bring it up.
Who Is Disabled?
Jacques Chambers, CLU
Jacques Chambers, CLU
The term "disability" or "disabled" is heard frequently, especially when discussing medical conditions such as hepatitis B or C, which tend to be progressive in their symptoms and can lead to an inability to work. The word is used in so many contexts, however, that it has become virtually generic to mean any type of limitation. It really has no special meaning other than describing a condition of some sort that prevents a person from doing something.
Alan Franciscus, Editor-in-Chief
This month’s column discusses Merck’s application to the FDA, BMS’s Breakthrough Designation, a pharmaceutical collaboration, and some relief for patients with high co-payments for HCV medications.
Genotype 5:
Alan Franciscus, Editor-in-Chief
Alan Franciscus, Editor-in-Chief
Genotype 5 is the least studied and the least prevalent. However, it is one of most mysterious…
What's New:
Alan Franciscus, Editor-in-Chief
Alan Franciscus, Editor-in-Chief
Updated Easy C Facts This month we have updated most of our Easy C Fact Series fact sheets. Check them out!
Strategies for Hepatitis C Treatment Access
Over at NVHR - National Viral Hepatitis Roundtable, sit back and listen to "Webinar: Strategies for Hepatitis C Treatment Access" which aired just last week.
This webinar has been archived:
download webinar slides
download webinar recording or log in to listen to recording here
To learn more about NVHR's program, visit http://nvhr.org/program
Questions or comments? Email Tina Broder, Senior Program Manager, tbroder@nvhr.org
Related:
Not Just another Hepatitis C Rant
By Lucinda K. Porter, RN
I can rant and rail about insurance and Medicaid denials of coverage for hepatitis C treatment, but I am trying to avoid blood pressure medications. Last week, I listened to an NVHR webinar of experts sharing their experiences trying to obtain prescription coverage for hepatitis C patients. My horror increased as I heard stories about denial after denial. One patient couldn't get a lung transplant until her hep C was treated. Another went through such a horrendous nightmare of denials and appeals that an old anxiety problem kicked back in. There are many stories like this one,..
No comments:
Post a Comment